MedTrace Logo

European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT02495974 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1763

Last updated 2024-10-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined as the time from baseline (treatment initiation) to treatment discontinuation of enzalutamide for any reason including disease progression, skeletal related events, treatment toxicity, patient preference, or death.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

enzalutamide

oral

Sponsors & Collaborators

  • Medivation, Inc.

    collaborator INDUSTRY

  • Astellas Pharma Europe Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Research Physician · Astellas Pharma Europe Ltd.

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-08
Primary Completion
2019-02-08
Completion
2019-02-08

Countries

  • Austria
  • Belgium
  • Bulgaria
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Netherlands
  • Portugal
  • Slovenia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02495974 on ClinicalTrials.gov